BASIC INFORMATION

Date & Time:

• 24 July 2024 | 14:00 IST

Lecture Handout Prepared from the Teaching Session by: Dr. R. K. Mishra

SUMMARY

This lecture provides a comprehensive overview of oral hormonal contraceptives (OHCs), detailing their fundamental principles, mechanism of action, and the significant trends that have shaped their development and clinical use since their introduction in 1960. The discussion covers the evolution from high-dose to low-dose estrogen formulations, the development of newer generations of progestins with improved side-effect profiles, and changes in administration regimens from standard monthly cycles to extended and continuous use. The lecture systematically explains the mechanism of action, focusing on ovulation inhibition, endometrial alteration, and changes in cervical mucus. It outlines the extensive non-contraceptive benefits, including cycle regulation and reduced risk of certain cancers, alongside a detailed analysis of both minor and major side effects, particularly cardiovascular risks. The lecture concludes with a discussion on contraindications, patient selection based on WHO Medical Eligibility Criteria, management of missed pills, and a brief overview of progestin-only pills (POPs).

KEY KNOWLEDGE POINTS

• Classification of oral hormonal contraceptives based on hormonal composition (combined vs. progestin-only).

• Evolutionary trends in OHCs: reduction in estrogen dose, development of newer progestin generations, and changes in administration regimens.

• The primary mechanism of action: suppression of the hypothalamic-pituitary-ovarian axis leading to inhibition of ovulation.

• Secondary mechanisms: alteration of the endometrium, thickening of cervical mucus, and changes in tubal motility.

• Extensive non-contraceptive benefits of combined OHCs, including cancer risk reduction and management of menstrual disorders.

• Common and major side effects, with a focus on cardiovascular and thromboembolic risks.

• Absolute and relative contraindications for OHC use based on WHO Medical Eligibility Criteria.

• Principles of progestin-only pills (POPs), their indications, and disadvantages.

• Practical guidelines for initiating OHCs and managing missed pills.

INTRODUCTION

Oral hormonal contraceptives, first introduced in 1960, revolutionized reproductive health and family planning. While their primary function is contraception, their hormonal components have been leveraged for a wide array of therapeutic applications in gynecology. These agents contain either a combination of estrogen and progestin (combined oral contraceptives, or COCs) or progestin alone (progestin-only pills, or POPs). Although the basic composition has remained consistent for over five decades, significant advancements have occurred. These evolving trends include dose reduction, the introduction of novel hormones, and modified administration schedules, all aimed at enhancing efficacy, improving tolerability, and minimizing adverse effects. This lecture will explore the fundamental pharmacology, mechanism of action, and the progressive changes that define modern oral contraceptive therapy.

LEARNING OBJECTIVES

• To understand the classification and composition of different types of oral hormonal contraceptives.

• To describe the primary and secondary mechanisms of action of combined and progestin-only pills.

• To identify the key trends in the evolution of oral contraceptives, including changes in dose, progestin type, and regimens.

• To list the contraceptive and significant non-contraceptive benefits of oral contraceptive use.

• To recognize the major side effects, contraindications, and medicolegal considerations associated with prescribing oral contraceptives.

CORE CONTENT

1. Historical Trends in Oral Contraceptive (OC) Pill Development

Four major trends have characterized the evolution of OC pills:

1.1. Reduction in Estrogen Dose

• Initial Formulations (High-Dose): Early pills contained high doses of the estrogen component, typically 50 mcg of ethinyl estradiol. This was associated with a significant incidence of thromboembolic events and other metabolic side effects.

• Low-Dose Formulations: The estrogen dose was subsequently reduced to 30 mcg, creating "low-dose" pills with an improved safety profile.

• Very Low-Dose Formulations: Current formulations often contain "very low-dose" estrogen, in the range of 15 to 35 mcg of ethinyl estradiol, which has further minimized estrogen-related adverse effects.

1.2. Development of Newer Progestins (Generations)

The androgenic side effects of early progestins prompted the development of newer, more selective agents.

• First Generation: Contained norethindrone, which exhibited notable androgenic properties.

• Second Generation: Utilized levonorgestrel, a more potent progestin with reduced androgenicity. Examples include government-supplied formulations in India like Mala-D and Mala-N.

• Third Generation: Introduced progestins such as desogestrel and norgestimate, which have very low androgenic activity.

• Fourth Generation: Comprises anti-androgenic progestins. These include drospirenone (a spironolactone analog) and dienogest. Cyproterone acetate, another fourth-generation agent, is particularly effective in managing hyperandrogenic conditions like Polycystic Ovary Syndrome (PCOS), addressing symptoms like hirsutism and acne.

1.3. Changes in Pill Regimen

• Sequential Regimen (Obsolete): Early regimens mimicked the natural menstrual cycle by providing estrogen alone in the first half and a combination of estrogen and progestin in the second half. This was abandoned due to an increased risk of endometrial cancer from unopposed estrogen exposure.

• Combined Regimen (Current Standard):

  • Monophasic: All active pills in the pack contain the same fixed dose of estrogen and progestin. This is the most common regimen due to its simplicity and good patient compliance. Standard schedules are 21 active pills followed by a 7-day pill-free interval (21+7) or 24 active pills followed by a 4-day pill-free interval (24+4). The shorter pill-free interval of the 24+4 regimen provides better ovarian suppression and fewer hormonal withdrawal symptoms.

  • Multiphasic (Biphasic, Triphasic): The dose of estrogen and/or progestin varies throughout the cycle. These regimens were designed to more closely mimic natural hormonal fluctuations and reduce the total hormone dose, but they are less popular due to a higher incidence of irregular bleeding and the need for strict adherence to the pill sequence. An example is Qlaira (Clara), which contains estradiol valerate and dienogest in varying doses.

1.4. Introduction of Natural Estrogens

To improve tolerability and reduce hepatic side effects, synthetic ethinyl estradiol is being replaced by natural estrogens like 17-beta estradiol or estradiol valerate in some newer formulations. The multiphasic pill Qlaira (Clara) is a prime example, combining a natural estrogen with a fourth-generation progestin (dienogest).

2. Mechanism of Action

OC pills exert their contraceptive effect through multiple synergistic mechanisms.

• 1. Inhibition of Ovulation (Primary Mechanism): OC pills suppress the hypothalamic-pituitary-ovarian (HPO) axis. The exogenous estrogen and progestin exert negative feedback on the hypothalamus, inhibiting the pulsatile release of Gonadotropin-Releasing Hormone (GnRH). This leads to suppressed pituitary secretion of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).

  • The estrogen component primarily suppresses FSH secretion, preventing follicular development.

  • The progestin component primarily suppresses the mid-cycle LH surge, which is the direct trigger for ovulation.

  The result is a hormonal environment with consistently low levels of FSH and LH, preventing follicular maturation and ovulation. This mechanism is effective even with low-dose formulations.

• 2. Alteration of the Endometrium: Continuous exposure to progestin renders the endometrium thin, atrophic, and poorly vascularized. The endometrial glands become exhausted and less secretory. This hostile endometrial environment prevents blastocyst implantation, even if fertilization were to occur. This effect also leads to scantier menstrual flow (withdrawal bleeding) with long-term use.

• 3. Changes in Cervical Mucus: Progestin makes the cervical mucus thick, scanty, and viscous. This change impairs sperm penetration into the uterine cavity. The characteristic mid-cycle properties of spinnbarkeit (stretchability) and ferning (crystallization pattern) are lost, creating a cervical barrier to sperm.

• 4. Alteration of Tubal Transport: OC pills may alter the motility of the fallopian tubes, affecting the transport of both sperm and ova. This is considered a minor contributory mechanism.

3. Efficacy

• Perfect Use: With consistent and correct administration, the failure rate is extremely low, approximately 0.1% (1 per 1000 woman-years).

• Typical Use: In real-world conditions, accounting for missed pills or incorrect use, the failure rate is significantly higher, ranging from 1.8% to 8%.

Common causes of failure include missed pills, delay in starting a new pack, and premature discontinuation due to side effects without medical consultation.

4. Non-Contraceptive Benefits

Combined OC pills offer numerous established health benefits beyond contraception:

• Cycle Regulation: Induce regular, predictable withdrawal bleeding and can be used to manage Abnormal Uterine Bleeding (AUB) or postpone menstruation.

• Menstrual Disorder Management:

  • Dysmenorrhea: By inhibiting ovulation, OC pills effectively treat primary dysmenorrhea.

  • Menorrhagia: The atrophic effect on the endometrium significantly reduces menstrual blood loss.

  • Premenstrual Syndrome (PMS): Stabilizing hormonal fluctuations can alleviate PMS symptoms.

• Protection Against Cancer: Long-term use is associated with a substantially reduced risk of:

  • Ovarian Cancer: (40-80% reduction) due to suppression of incessant ovulation.

  • Endometrial Cancer: (50% reduction) due to the protective effect of the progestin component. This protective effect persists for years after discontinuation.

• Protection Against Benign Conditions:

  • Benign Breast Disease: Reduced incidence of fibrocystic changes.

  • Functional Ovarian Cysts: Suppression of follicular development prevents their formation.

  • Pelvic Inflammatory Disease (PID): Thickened cervical mucus acts as a barrier to ascending infection. Note: If a PID infection does occur in an OC pill user, Chlamydia is the most common causative organism.

• Other Benefits:

  • Ectopic Pregnancy: Reduced risk due to ovulation inhibition.

  • Acne and Hirsutism: Anti-androgenic effects of certain progestins (e.g., cyproterone acetate, drospirenone) are therapeutic.

  • Iron-Deficiency Anemia: Reduced menstrual blood loss helps prevent anemia.

Emerging evidence suggests potential benefits in reducing the risk of colorectal cancer and protecting against bone loss.

5. Progestin-Only Pills (POPs) or "Mini-Pills"

POPs contain only a low dose of progestin and no estrogen.

• Mechanism: Their primary mechanism is thickening of cervical mucus. They also create a hostile endometrium. Ovulation is inhibited in only about 60% of cycles.

• Indications: POPs are a suitable choice for women in whom estrogen is contraindicated, such as:

  • Lactating women (estrogen can suppress milk production).

  • Women with a history of venous thromboembolism (VTE).

  • Smokers over the age of 35.

  • Women with hypertension or other cardiovascular risk factors.

• Disadvantages:

  • Stricter Adherence: Must be taken at the same time each day (within a 3-hour window).

  • Irregular Bleeding: Breakthrough bleeding and spotting are very common due to the lack of estrogen to stabilize the endometrium.

  • Slightly Lower Efficacy: Less effective than combined OC pills.

SURGICAL PEARLS

• When a patient on OC pills presents with pelvic inflammatory disease (PID), the most likely causative organism is Chlamydia trachomatis.

• Vaginal candidiasis is a common side effect in OC pill users due to hormonal changes affecting the vaginal environment.

• The fourth-generation progestin dienogest is not only used in contraceptives but is also a primary medical treatment for endometriosis.

• For postponing menstruation, the active pills of a monophasic regimen can be continued without taking the 7-day pill-free break.

• Fertility returns rapidly after discontinuing standard monthly OC pill regimens. For extended regimens (e.g., 84 days), ovulation typically resumes within one month, and menstruation returns within 90 days.

COMPLICATIONS AND THEIR MANAGEMENT

Minor Side Effects

These are common in the first 2-3 cycles and are usually transient. They are often related to the estrogen component and include:

• Nausea and vomiting

• Breast tenderness (due to fluid retention)

• Headache

• Weight gain (minor)

• Mood changes

• Breakthrough bleeding (BTB) or spotting

Management: Reassurance and counseling are key. Symptoms typically resolve with continued use. If persistent, a change in formulation may be considered.

Major Side Effects

These are rare but potentially life-threatening.

• Cardiovascular Risks:

  • Venous Thromboembolism (VTE): Deep vein thrombosis and pulmonary embolism. The risk is primarily associated with the estrogen component.

  • Arterial Thrombosis: Myocardial infarction and stroke.

  • Risk Factors: The risk is significantly amplified by smoking, age >35 years, obesity, and hypertension. A combination of smoking and being over 35 is a strong contraindication.

• Carcinogenicity:

  • Breast Cancer: A slight increase in relative risk, which appears to diminish after discontinuation.

  • Cervical Cancer: A potential association, possibly confounded by sexual behavior.

• Hepatic Disorders:

  • Cholestatic jaundice

  • Gallstone formation

  • Benign liver tumors (hepatic adenoma)

MEDICOLEGAL AND PATIENT SELECTION CONSIDERATIONS

A thorough medical history is mandatory before prescribing OC pills to identify contraindications. The World Health Organization (WHO) Medical Eligibility Criteria (MEC) provides a framework for safe prescribing:

• Category 1: No restrictions.

• Category 2: Advantages generally outweigh theoretical or proven risks.

• Category 3: Theoretical or proven risks usually outweigh the advantages; use requires expert clinical judgment.

• Category 4: Unacceptable health risk; the method should not be used.

Absolute Contraindications (WHO Category 4):

• History of or current venous thromboembolism (VTE), stroke, or coronary artery disease.

• Known thrombogenic mutations.

• Smoker >35 years of age (≥15 cigarettes/day).

• Uncontrolled hypertension.

• Known or suspected breast cancer.

• Estrogen-dependent neoplasia.

• Undiagnosed abnormal genital bleeding.

• Known or suspected pregnancy.

• Active liver disease (e.g., severe cirrhosis, liver tumors).

Relative Contraindications (WHO Category 2 or 3):

• Age >45 years.

• Controlled hypertension.

• Diabetes with vascular complications.

• History of cholestasis of pregnancy.

• Hyperlipidemia.

• Major surgery with prolonged immobilization.

SUMMARY AND TAKE-HOME MESSAGES

• Oral contraceptives have evolved significantly, with modern formulations featuring lower estrogen doses and newer-generation progestins to maximize safety and tolerability.

• The primary mechanism of action is the reliable inhibition of ovulation through suppression of the HPO axis, supported by secondary effects on the endometrium and cervical mucus.

• In addition to highly effective contraception, combined OC pills offer substantial non-contraceptive benefits, including a reduced risk of ovarian and endometrial cancer, and effective management of various menstrual disorders.

• Careful patient selection is paramount. A thorough history must be taken to screen for contraindications, especially cardiovascular risk factors like smoking, hypertension, and a history of thromboembolism.

• Patient counseling on managing minor side effects, the importance of daily compliance, and the protocol for missed pills is essential for ensuring efficacy and adherence.

MULTIPLE CHOICE QUESTIONS (MCQs)

1. What is the primary mechanism of action of combined oral contraceptives?

   a) Thickening of cervical mucus

   b) Inhibition of ovulation

   c) Alteration of the endometrium

   d) Impairment of tubal motility

2. Which component of combined OC pills is primarily responsible for suppressing the LH surge?

   a) Ethinyl estradiol

   b) Progestin

   c) Placebo pills

   d) Estradiol valerate

3. Drospirenone, a fourth-generation progestin, is an analog of which of the following compounds?

   a) Testosterone

   b) Norethindrone

   c) Spironolactone

   d) Progesterone

4. Which generation of OC pills contains levonorgestrel and includes formulations like Mala-D and Mala-N?

   a) First generation

   b) Second generation

   c) Third generation

   d) Fourth generation

5. The use of sequential OC regimens was abandoned due to an increased risk of which condition?

   a) Ovarian cancer

   b) Endometrial cancer

   c) Breast cancer

   d) Cervical cancer

6. A 24+4 monophasic regimen offers which advantage over a traditional 21+7 regimen?

   a) Higher total monthly hormone dose

   b) Longer pill-free interval

   c) Better suppression of ovulation and fewer withdrawal symptoms

   d) Lower risk of breakthrough bleeding

7. Which of the following is an established non-contraceptive benefit of long-term combined OC pill use?

   a) Increased risk of ovarian cancer

   b) Reduced risk of endometrial cancer

   c) Increased risk of ectopic pregnancy

   d) Increased risk of benign breast disease

8. Which of the following is considered an absolute contraindication (WHO Category 4) for prescribing combined OC pills?

   a) Age over 45

   b) History of migraine without aura

   c) A current deep vein thrombosis (DVT)

   d) Controlled hypertension

9. A woman taking OC pills develops vaginitis. What is the most common causative organism?

   a) Gardnerella vaginalis

   b) Chlamydia trachomatis

   c) Trichomonas vaginalis

   d) Candida albicans

10. The progestin cyproterone acetate is particularly useful for treating which of the following conditions?

    a) Endometriosis

    b) Menorrhagia

    c) Hirsutism and acne in PCOS

    d) Premenstrual syndrome

11. What is the primary mechanism of action for progestin-only pills (POPs)?

    a) Consistent inhibition of ovulation in all cycles

    b) Thickening of cervical mucus

    c) Proliferation of the endometrium

    d) Suppression of FSH release

12. A patient on a 28-day OC pill cycle misses one active pill in the first week. What is the correct advice?

    a) Discard the pack and start a new one.

    b) Take the missed pill immediately and the next pill at the usual time; no backup contraception is needed.

    c) Stop taking pills for 7 days.

    d) Take the missed pill and use a backup method for 7 days.

13. The shift from synthetic ethinyl estradiol to natural estrogens like estradiol valerate aims to reduce which type of side effects?

    a) Androgenic side effects

    b) Hepatic and metabolic disorders

    c) Irregular bleeding

    d) Nausea and vomiting

14. What defines a "very low-dose" oral contraceptive pill?

    a) Estrogen component of 50 mcg

    b) Estrogen component of around 20 mcg

    c) Progestin-only formulation

    d) Estrogen component of 30 mcg

15. Extended or continuous OC regimens, such as taking pills for 84 days continuously, are designed for what purpose?

    a) To increase the risk of endometrial cancer

    b) To reduce the number of menstrual periods per year

    c) To enhance fertility immediately after stopping

    d) To treat active thromboembolic disease

16. Which of the following conditions is a major risk associated with combined OC pill use, especially in smokers over 35?

    a) Pelvic inflammatory disease

    b) Functional ovarian cysts

    c) Venous thromboembolism (VTE)

    d) Iron-deficiency anemia

17. If a patient misses two consecutive active pills in the third week of her cycle, what is the recommended course of action?

    a) Continue the pack as normal.

    b) Take both missed pills at once and continue the pack.

    c) Discard the current pack, use a backup method for 7 days, and start a new pack immediately.

    d) Skip the placebo pills and start a new pack immediately.

18. Progestin-only pills are a preferred contraceptive choice for which group of women?

    a) Women with severe acne

    b) Women who are breastfeeding

    c) Women seeking to regulate heavy menstrual bleeding

    d) Adolescents under 18

19. The introduction of third-generation progestins like desogestrel aimed to reduce which specific side effect?

    a) Water retention

    b) Androgenic effects

    c) Thromboembolic risk

    d) Nausea

20. What is the most common cause of OC pill failure in "typical use"?

    a) Drug interactions with antibiotics

    b) High body mass index (BMI)

    c) Missed pills or incorrect use

    d) Underlying malabsorption syndrome

MCQ Answers: 1-b, 2-b, 3-c, 4-b, 5-b, 6-c, 7-b, 8-c, 9-d, 10-c, 11-b, 12-b, 13-b, 14-b, 15-b, 16-c, 17-c, 18-b, 19-b, 20-c

MOTIVATIONAL MESSAGE FROM DR. R. K. MISHRA

"Each step of a procedure, no matter how routine, is a fresh promise of safety and excellence to your patient. Fulfill this promise not with haste, but with unwavering attention and disciplined skill."

May your dedication to continuous learning translate into superior care and confidence in your practice. My best wishes are with you all.